Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs CRN-00808 (Primary) ; CRN-00808 (Primary) ; Midazolam
  • Indications Acromegaly
  • Focus Adverse reactions; First in man
  • Sponsors Crinetics Pharmaceuticals
  • Most Recent Events

    • 27 Aug 2018 Status changed from recruiting to completed.
    • 20 Mar 2018 Results from the single-dose arm part of this trial (n=8/cohort), presented at The 100th Annual Meeting of the Endocrine Society.
    • 12 Mar 2018 According to a Crinetics Pharmaceuticals media release, data from this trial will be presented at the upcoming ENDO 2018, the Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top